ISIS PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTSOFCOMPREHENSIVELOSS
(In thousands)
Years Ended December 31,
2014
2013
2012
Net loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $(38,984) $(60,644) $(65,478)
Unrealized gains on investments, net of tax . . . . . . . . . . . . . . . . . . . . . . . . . . .
40,079 10,253 13,250
Reclassification adjustment for realized gains included in net loss . . . . . . . . .
(21,412)
(1,653)
—
Comprehensive loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $(20,317) $(52,044) $(52,228)
See accompanying notes.
F-5
